Pharmala Biotech Holdings (XCNQ:MDMA) Current Accrued Expense : C$0.37 Mil (As of Feb. 2025)

View and export this data going back to 2022. Start your Free Trial

What is Pharmala Biotech Holdings Current Accrued Expense?

Pharmala Biotech Holdings's Current Accrued Expense for the quarter that ended in Feb. 2025 was C$0.37 Mil.

Pharmala Biotech Holdings's quarterly Current Accrued Expense increased from Aug. 2024 (C$0.19 Mil) to Nov. 2024 (C$0.28 Mil) and increased from Nov. 2024 (C$0.28 Mil) to Feb. 2025 (C$0.37 Mil).

Pharmala Biotech Holdings's annual Current Accrued Expense declined from Aug. 2022 (C$0.37 Mil) to Aug. 2023 (C$0.27 Mil) and declined from Aug. 2023 (C$0.27 Mil) to Aug. 2024 (C$0.19 Mil).

Pharmala Biotech Holdings Current Accrued Expense Historical Data

The historical data trend for Pharmala Biotech Holdings's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmala Biotech Holdings Current Accrued Expense Chart

Pharmala Biotech Holdings Annual Data

Trend

Aug21

Aug22

Aug23

Aug24

Current Accrued Expense

0.14

0.37

0.27

0.19

Pharmala Biotech Holdings Quarterly Data
	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	Aug24	Nov24	Feb25
Current Accrued Expense	Get a 7-Day Free Trial										0.60	0.74	0.19	0.28	0.37

Pharmala Biotech Holdings Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Pharmala Biotech Holdings Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Pharmala Biotech Holdings's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmala Biotech Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (XCNQ:MDMA) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

MDXXF:USA

Address

1 Adelaide Street East, Suite 801, Toranto, ON, CAN, M5C 2V9

Website

https://www.pharmala.ca

Pharmala Biotech Holdings Inc is focused on manufacturing and sales of MDMA and MDXX Active Pharmaceutical Ingredients (API) for use in clinical research. Its drug API is manufactured and encapsulated under GMP conditions. The company generates revenue from the sale of tablets and raw MDMA and MDXX compounds/formulations and royalties from licensing of its IP.

Executives

Fraser Macdonald	Director
Perry Tsergas	Director
Shane H.d. Morris	Director, Senior Officer
Nicholas Kadysh	Director, Senior Officer

Pharmala Biotech Holdings Headlines

No Headlines